Table 2.

ToxNav® variant results across patient characteristic and initial chemotherapy dose

	Standard (n = 139)	rs12132152 HFS (n = 31)	rs2612091 HFS (n = 280)	rs3918290 Critical (n = 7)	rs67376798 High(n = 9)	No-ToxNav (n = 1556)
	Count (column %, row %)	Count (column %, row %)	Count (column %, row %)	Count (column %, row %)	Count (column %, row %)	Count (column %)
Result classification*
HFS	0 (0%)	31 (100, 10%)	280 (100, 90%)	0 (0%)	0 (0%)	NA
High/critical toxicity	0 (0%)	0 (0%)	0 (0%)	7 (100, 44%)	9 (100, 56%)	NA
Standard	139 (100, 100%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	NA
Race
Caucasian	91 (65, 30%)	24 (77, 8%)	179 (64, 59%)	4 (57, 1%)	6 (67, 2%)	1079 (69%)
Asian	4 (3, 67%)	0 (0, 0%)	2 (1, 33%)	0 (0, 0%)	0 (0, 0%)	28 (2%)
African	1 (1, 50%)	0 (0, 0%)	1 (0, 50%)	0 (0, 0%)	0 (0, 0%)	15 (1%)
Other/unknown	43 (31, 28%)	7 (23, 5%)	98 (35, 64%)	3 (43, 2%)	3 (33, 2%)	3 (0%)
Tumour site
Upper GI	19 (16, 27%)	4 (17, 6%)	45 (19, 63%)	1 (20, 1%)	2 (33, 3%)	299 (19%)
Lower GI	53 (45, 32%)	8 (33, 5%)	101 (42, 60%)	2 (40, 1%)	3 (50, 2%)	724 (47%)
Breast	35 (30, 30%)	8 (33, 7%)	71 (30, 61%)	2 (40, 2%)	1 (17, 1%)	382 (25%)
Other	10 (9, 29%)	4 (17, 11%)	21 (9, 60%)	0 (0, 0%)	0 (0, 0%)	132 (8%)
Initial Capecitabine dose*
< 60%	0 (0, 0%)	0 (0, 0%)	4 (2, 50%)	2 (67, 25%)	2 (50, 25%)	36 (5%)
60–80%	7 (10, 21%)	1 (5, 3%)	25 (14, 74%)	1 (33, 3%)	0 (0, 0%)	120 (15%)
80–100%	60 (90, 27%)	19 (95, 8%)	144 (84, 64%)	0 (0, 0%)	2 (50, 1%)	630 (80%)
Initial 5FU dose*
< 60%	5 (11, 45%)	0 (0, 0%)	2 (3, 18%)	1 (100, 9%)	3 (100, 27%)	27 (5%)
60–80%	5 (11, 31%)	2 (40, 13%)	9 (14, 56%)	0 (0, 0%)	0 (0, 0%)	69 (12%)
80–100%	34 (77, 38%)	3 (60, 3%)	52 (83, 58%)	0 (0, 0%)	0 (0, 0%)	461 (83%)

* p-value< 0.05 based on Chi-square test; Note: patients who received Capecitabine or 5FU prior to ToxNav test are excluded from the dose related variables displayed in this table; Initial dose refers to dose at the first cycle of treatment; rs3918290 and rs67376798 variant alleles were all heterozygote. NA: Not applicable